BIOMAT Database Logo BIOMAT Database Logo

Is troglitazone a real indication for obese subjects with impaired glucose tolerance? 1997

K Yoshioka, and S Yokoo, and T Yoshida, and M Kondo

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D009765 Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
D002839 Chromans Benzopyrans saturated in the 2 and 3 positions. Dihydrobenzopyrans
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077288 Troglitazone A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity. 5-(4-((6-Hydroxy-2,5,7,8-tetramethylchroman-2-yl-methoxy)benzyl)-2,4-thiazolidinedione) - T,CS 045,CS-045,Prelay,Rezulin,CS045
D013844 Thiazoles Heterocyclic compounds where the ring system is composed of three CARBON atoms, a SULFUR and NITROGEN atoms. Thiazole
D045162 Thiazolidinediones THIAZOLES with two keto oxygens. Members are insulin-sensitizing agents which overcome INSULIN RESISTANCE by activation of the peroxisome proliferator activated receptor gamma (PPAR-gamma). Glitazones
D018149 Glucose Intolerance A pathological state in which BLOOD GLUCOSE level is less than approximately 140 mg/100 ml of PLASMA at fasting, and above approximately 200 mg/100 ml plasma at 30-, 60-, or 90-minute during a GLUCOSE TOLERANCE TEST. This condition is seen frequently in DIABETES MELLITUS, but also occurs with other diseases and MALNUTRITION. Impaired Glucose Tolerance,Glucose Intolerances,Glucose Tolerance, Impaired,Glucose Tolerances, Impaired,Impaired Glucose Tolerances,Intolerance, Glucose,Intolerances, Glucose,Tolerance, Impaired Glucose,Tolerances, Impaired Glucose

Related Publications

K Yoshioka, and S Yokoo, and T Yoshida, and M Kondo
Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone.
February 1997, Diabetes care,
K Yoshioka, and S Yokoo, and T Yoshida, and M Kondo
Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
November 1994, The New England journal of medicine,
K Yoshioka, and S Yokoo, and T Yoshida, and M Kondo
Plasma interleukin 8 concentrations in obese subjects with impaired glucose tolerance.
May 2003, Cardiovascular diabetology,
K Yoshioka, and S Yokoo, and T Yoshida, and M Kondo
Evaluation of insulin resistance in non-obese subjects with impaired glucose tolerance.
September 1982, Diabete & metabolisme,
K Yoshioka, and S Yokoo, and T Yoshida, and M Kondo
Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance.
August 1997, The Journal of clinical investigation,
K Yoshioka, and S Yokoo, and T Yoshida, and M Kondo
Plasma glucagon suppressibility after oral glucose in obese subjects with normal and impaired glucose tolerance.
December 1984, Metabolism: clinical and experimental,
K Yoshioka, and S Yokoo, and T Yoshida, and M Kondo
Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance.
May 2004, Metabolism: clinical and experimental,
K Yoshioka, and S Yokoo, and T Yoshida, and M Kondo
Serum Galanin Concentration is Increased in Subjects with Impaired Glucose Tolerance.
December 2017, Canadian journal of diabetes,
K Yoshioka, and S Yokoo, and T Yoshida, and M Kondo
[Exercise therapy for obese impaired glucose tolerance patients].
February 2005, Nihon rinsho. Japanese journal of clinical medicine,
K Yoshioka, and S Yokoo, and T Yoshida, and M Kondo
[Skin needle embedding for obese impaired glucose tolerance].
January 2018, Zhongguo zhen jiu = Chinese acupuncture & moxibustion,
Copied contents to your clipboard!